BMS-1

• Description:

  BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) [1][2].

• Product Name Alternative:

  PD-1/PD-L1 inhibitor 1

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/PD1-PDL1-inhibitor-1.html

• Concentration:

  10mM

• Purity:

  99.71

• Solubility:

  DMF : 5 mg/mL (ultrasonic) |DMSO : 7.14 mg/mL (ultrasonic) |Methanol : 25 mg/mL (ultrasonic)

• Smiles:

  O=C([C@H]1N(CC2=C(OC)C=C(OCC3=C(C)C(C4=CC=CC=C4)=CC=C3)C=C2OC)CCCC1)O

• Molecular Formula:

  C29H33NO5

• Molecular Weight:

  475.58

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4.|[2]Li K, et al. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019 Mar;27 (3) :244-256.|[3]Zhang H, et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 2019 Apr 3;37 (15) :2090-2098.|[4]Mengyuan Li, et al. KALRN mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020 Oct;8 (2) :e000293.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1675201-83-8]